US Patent 11512080 CRBN ligands and uses thereof
Patent 11512080 was granted and assigned to Kymera Therapeutics on November, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115120800
Date of Patent
November 29, 2022
0Patent Application Number
169613620
Date Filed
January 14, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 30 Nov, 2022
Golden AI
Edits made to:
Infobox (+14 properties)
Article (+167 characters)
US Patent 11512080 CRBN ligands and uses thereof
Article
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115120800
Date of Patent
November 29, 2022
0Patent Application Number
169613620
Date Filed
January 14, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11512080 CRBN ligands and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.